Tesamorelin peptide guide

Tesamorelin tells your pituitary gland to release growth hormone in natural pulses, rather than putting growth hormone directly into your blood. After a subcutaneous injection, the peptide binds to GHRH receptors on cells in the anterior pituitary called somatotrophs, which then release stored growth hormone. That growth hormone travels to the liver and triggers production of insulin-like growth factor-1 (IGF-1), which is the downstream signal that drives most of tesamorelin's measurable effects on body composition.

The pulsatile pattern matters because it preserves the body's normal feedback loops. Direct human growth hormone (HGH) injections raise IGF-1 continuously and can suppress the pituitary's own output over time. Tesamorelin works upstream, so growth hormone secretion stays regulated by the body and IGF-1 rises moderately rather than continuously.

The strongest measurable effect from this signaling cascade is lipolysis (fat breakdown) in visceral adipose tissue — the deep abdominal fat surrounding the organs. Effects on subcutaneous fat are not statistically meaningful in trial data, which is why tesamorelin reduces waist circumference but not surface-level fat the way GLP-1 medications can.

The strongest evidence comes from the Phase 3 program that earned tesamorelin its FDA approval. In Falutz et al. (NEJM 2007), 412 adults with HIV-associated lipodystrophy received either 2 mg tesamorelin daily or placebo for 26 weeks. Visceral adipose tissue (VAT) decreased by 15.2% in the tesamorelin group versus 5.0% in placebo (P < 0.001). The replication trial, Falutz et al. (JAIDS 2010), enrolled 404 patients on the same protocol and reported an 18.4% VAT reduction versus 2.2% in placebo, with safety extension data out to 52 weeks.

A separate JAMA-published trial by Stanley et al. (2014) randomized 50 antiretroviral-treated adults with HIV and abdominal fat to 2 mg tesamorelin or placebo for 6 months. The tesamorelin group lost a mean of 34 cm² of visceral adipose tissue while the placebo group gained 8 cm², and liver fat dropped by a relative 40% in the tesamorelin group versus a 27% rise in placebo. A larger 12-month NAFLD-specific trial (Stanley et al., Lancet HIV 2019) replicated the liver-fat finding in 61 adults with HIV and non-alcoholic fatty liver disease and reported attenuated fibrosis progression compared to placebo.

Beyond body composition, Baker et al. (Arch Neurol 2012) tested 1 mg tesamorelin daily for 20 weeks in 137 older adults — both healthy and with mild cognitive impairment — and reported improvements in executive function and verbal memory versus placebo. I checked this finding in the published paper directly because it is widely cited but rarely contextualized: the trial used a single dose, a single duration, and a small population, and the cognitive improvement has not been replicated in a larger Phase 3 trial.

The clear evidence boundary: every large, replicated tesamorelin trial was conducted in adults with HIV. Body-composition data in non-HIV populations is limited to small studies and clinical observation. No randomized controlled trial in healthy adults has ever tested tesamorelin specifically for cosmetic visceral fat reduction outside of an HIV context.

In the Phase 3 program, the most common adverse events were injection site reactions, peripheral edema, joint pain (arthralgia), muscle pain (myalgia), tingling or numbness (paresthesia), and headache. Adverse events were reported in roughly 68% of participants in the cognitive trial and a similar proportion in the lipodystrophy trials, but most were mild and localized. Approximately 56% of patients in pooled trial data developed antibodies to tesamorelin after 26 weeks, though the clinical significance of those antibodies remains limited.

The FDA label carries specific warnings that go beyond the common side effects. Tesamorelin can cause glucose intolerance — the label requires evaluating glucose status before initiating and monitoring periodically during therapy. The growth hormone-stimulating effect is the basis for the label's contraindication in patients with active malignancy: I verified this contraindication against the EGRIFTA prescribing information on DailyMed. Tesamorelin is also contraindicated in patients with hypopituitarism, pituitary tumors, or pituitary surgery, in patients with known hypersensitivity to tesamorelin or mannitol, and during pregnancy (FDA Pregnancy Category X — animal data showed hydrocephaly in offspring at clinically relevant doses).

As of April 2026, tesamorelin is FDA-approved only for HIV-associated lipodystrophy. EGRIFTA SV and EGRIFTA WR are the currently marketed formulations. Off-label prescribing exists in clinical practice but has no FDA-approved indication, and research-context use of unregulated grey-market tesamorelin carries an additional layer of contamination and purity risk that the FDA-labeled product does not. The trial-context doses used in published research were 1 mg/day (cognitive trial) and 2 mg/day (Phase 3 lipodystrophy trials). This is not a dosing recommendation — it is reporting of trial protocols.